Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed is benefiting from rapid adoption of its AI-enabled aprevo platform, with 3Q26 revenue of about $21.6M, up 64.9% Y/Y, driven by 60%+ surgeon growth and a 200.8% Y/Y increase in units per surgeon, while gross margin improved to 77.3%. The cervical franchise is gaining traction at roughly 12% of revenue, reimbursement is strengthening through CMS’s new higher-complexity DRG codes effective on October 1, 2026, and two product launches in 4Q26 should further lift ASPs and utilization. With FY26 revenue guidance raised to $78M-$80M, about $80M in cash and investments, and a long runway toward profitability from operating leverage, the company appears well positioned for continued above-peer growth.

Carlsmed is facing a bearish setup because its growth depends on faster adoption of aprevo by new surgeons, yet slower uptake, weaker spine market growth, and faster ASP degradation could materially pressure revenue expansion. The company also appears exposed to execution risk from poor sales, reimbursement headwinds, rising competition, delayed cervical-spine entry, and higher operating expenses, all of which could slow the path to profitability. In the bear case, revenue growth is assumed to decelerate to 10-20% over the modeling horizon, underscoring limited visibility into sustained commercial scaling and margin improvement.